New abilities to enhance cancer research at the Australian Synchrotron
It gave me great pleasure to today unveil the newest research tool that Australian scientists and researchers have in the fight against cancer. The Australian Synchrotron’s new multi-million dollar Australian Cancer Research Foundation (ACRF) Detector will fast-track new…
Opthea Launches A$45 Million Financing to Progress OPT- 302 Expanded Clinical Development
Opthea Limited (ASX:OPT) (“Opthea”), a developer of novel biologic therapies for the treatment of eye diseases, today announced the launch of an entitlement offer and institutional placement (collectively the “Offer”) to raise approximately A$45 million. Proceeds from the…
Lab-grown mini-organs help model disease, test new drugs
To the naked eye, the little globs of cells are undifferentiated masses, smaller than sesame seeds. Put them under a microscope, though, and these lab-grown miniature organs show striking complexity: the tiny tubules of a kidney, the delicate…
Australia’s new National Science Statement! The Australian Government long-term vision for science research and policy making
The Australian Government’s National Innovation and Science Agenda identified science as one of the critical elements for Australia to deliver new sources of growth, maintain high‑wage jobs and seize the next wave of economic prosperity. Science—including the natural,…
Easing the pain of global expansion
Two years after going global, Australian healthcare company Medical Developments International (MDI) which manufactures the acute pain killer Penthrox (commonly known as ‘the green whistle’) has opened a new facility in Melbourne Assisted by CSIRO, MDI has seen…
The US drug pricing debate: Managing risks to results
EY report on drug pricing The unsustainable trajectory of the health care spending in the US is generating much dialog and consternation across a variety of stakeholders including governments, industry, media academic think-tanks and the general public. Prescription…
New Director of Bio 21 announced
Professor Michael Parker has been appointed as the new Director of the University of Melbourne’s Bio 21 Molecular Science and Biotechnology Institute. One of Australia’s leading protein structural biologists, Prof Parker will take up the role as part…
Atomic map gives malaria drug new lease on life
Researchers have for the first time mapped how one of the longest-serving malaria drugs works, opening the possibility of altering its structure to make it more effective and combat increasing malaria drug resistance. The study produced a precise…
Catalyst for efficient drug and chemical production
A team of CSIRO scientists have made a breakthrough that could result in faster and cheaper production for the pharmaceutical, food and bulk chemistry industries. The team have developed a more efficient and simpler process that – when…
Medical Countermeasures EOI – Documentation release
The Defence Materials Technology Centre (DMTC) is a not for profit collaborative venture that brings together defence industry, universities and government research agencies to develop technologies that will enhance Australia’s defence and national security capability. The Medical Countermeasures…
Fellowship Brings Leading Cancer Researcher To Victoria
One of the world’s best cancer researchers working to accelerate future treatments through DNA repair has received support from the Andrews Labor Government and veski to undertake research here in Victoria. Minister for Small Business, Innovation and Trade…
Bone, cartilage and tissue; we’ve cracked the trifecta (and it’s made of titanium and plastic)
We’ve been quietly working away in Melbourne on something big. The big trifecta of a bone, cartilage and tissue implant. The first of its kind. More specifically, a 3D printed titanium and polymer sternum to suit individual patients. …
